305 related articles for article (PubMed ID: 20591136)
1. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
Maréchal R; De Schutter J; Nagy N; Demetter P; Lemmers A; Devière J; Salmon I; Tejpar S; Van Laethem JL
BMC Cancer; 2010 Jun; 10():340. PubMed ID: 20591136
[TBL] [Abstract][Full Text] [Related]
2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
3. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
5. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
7. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Sotelo MJ; García-Paredes B; Aguado C; Sastre J; Díaz-Rubio E
World J Gastroenterol; 2014 Apr; 20(15):4208-19. PubMed ID: 24764659
[TBL] [Abstract][Full Text] [Related]
8. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
9. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract][Full Text] [Related]
10. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
12. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A; Bachet JB; Boige V; Cayre A; Le Corre D; Buc E; Ychou M; Bouché O; Landi B; Louvet C; André T; Bibeau F; Diebold MD; Rougier P; Ducreux M; Tomasic G; Emile JF; Penault-Llorca F; Laurent-Puig P
J Clin Oncol; 2008 Jan; 26(3):374-9. PubMed ID: 18202412
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
15. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
[TBL] [Abstract][Full Text] [Related]
16. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
[TBL] [Abstract][Full Text] [Related]
17. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
[TBL] [Abstract][Full Text] [Related]
19. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
